The other five cases were associated with acquired deficiency due to treatment for Paroxysmal nocturnal hemoglobinuria (PNH) using monoclonal antibodies treatment (eculizumab or ravulizumab) against the C5 complement component (anti-C5 mAb). This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.